San Fransisco-based Ambrosia’s LinkBlueCon app is designed to monitor glucose levels and receive notifications when glucose readings are outside the target range, all without the need to go to a clinic.
Ambrosia said it will make it easier to see health and activity data, such as sleep, heart rate and cardio fitness, and how they can affect glucose levels, on its platform.
BluCon technology is sold for $110 and can be used to display glucose readings from FreeStyle Libre, and FreeStyle Libre 2 sensors on Apple and Huawei 2 watches without using a phone. The NightRider BluCon is currently used in more than 100 countries on the FreeStyle Libre platforms, Ambrosia said in a news release.
Abbott’s FreeStyle Libre mobile app won FDA approval in November 2018, and the company touted data from the glucose monitor in February of this year. Frequent users of the technology lowered their time in hypoglycemia by 31% compared to infrequent scanners, while users who scanned a second time within one hour of a low glucose event lessened the likelihood of prolonged hypoglycemia by 56%.
Chicago-based Abbott also won reimbursement for the FreeStyle Libre in Ontario and Quebec last week.
Shares of ABT were up 0.4% at $83.58 per share in late-morning trading today.